225 related articles for article (PubMed ID: 27001668)
1. Aminochrome induces dopaminergic neuronal dysfunction: a new animal model for Parkinson's disease.
Herrera A; Muñoz P; Paris I; Díaz-Veliz G; Mora S; Inzunza J; Hultenby K; Cardenas C; Jaña F; Raisman-Vozari R; Gysling K; Abarca J; Steinbusch HW; Segura-Aguilar J
Cell Mol Life Sci; 2016 Sep; 73(18):3583-97. PubMed ID: 27001668
[TBL] [Abstract][Full Text] [Related]
2. Aminochrome Induces Neuroinflammation and Dopaminergic Neuronal Loss: A New Preclinical Model to Find Anti-inflammatory and Neuroprotective Drugs for Parkinson's Disease.
De Araújo FM; Frota AF; de Jesus LB; Macedo TC; Cuenca-Bermejo L; Sanchez-Rodrigo C; Ferreira KMS; de Oliveira JVR; de Fatima Dias Costa M; Segura-Aguilar J; Costa SL; Herrero MT; Silva VDA
Cell Mol Neurobiol; 2023 Jan; 43(1):265-281. PubMed ID: 34988761
[TBL] [Abstract][Full Text] [Related]
3. Colchicine protects dopaminergic neurons in a rat model of Parkinson's disease.
Salama M; Ellaithy A; Helmy B; El-Gamal M; Tantawy D; Mohamed M; Sheashaa H; Sobh M; Arias-Carrión O
CNS Neurol Disord Drug Targets; 2012 Nov; 11(7):836-43. PubMed ID: 23198691
[TBL] [Abstract][Full Text] [Related]
4. Inhibitors of mitochondrial respiration, iron (II), and hydroxyl radical evoke release and extracellular hydrolysis of glutathione in rat striatum and substantia nigra: potential implications to Parkinson's disease.
Han J; Cheng FC; Yang Z; Dryhurst G
J Neurochem; 1999 Oct; 73(4):1683-95. PubMed ID: 10501216
[TBL] [Abstract][Full Text] [Related]
5. Further Characterization of Intrastriatal Lipopolysaccharide Model of Parkinson's Disease in C57BL/6 Mice.
Deng I; Corrigan F; Garg S; Zhou XF; Bobrovskaya L
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299000
[TBL] [Abstract][Full Text] [Related]
6. Adenosine A
Nunes ACL; Carmo M; Behrenswerth A; Canas PM; Agostinho P; Cunha RA
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732120
[TBL] [Abstract][Full Text] [Related]
7. Accumulation of mitochondrial DNA deletions within dopaminergic neurons triggers neuroprotective mechanisms.
Perier C; Bender A; García-Arumí E; Melià MJ; Bové J; Laub C; Klopstock T; Elstner M; Mounsey RB; Teismann P; Prolla T; Andreu AL; Vila M
Brain; 2013 Aug; 136(Pt 8):2369-78. PubMed ID: 23884809
[TBL] [Abstract][Full Text] [Related]
8. Aminochrome as a preclinical experimental model to study degeneration of dopaminergic neurons in Parkinson's disease.
Paris I; Cardenas S; Lozano J; Perez-Pastene C; Graumann R; Riveros A; Caviedes P; Segura-Aguilar J
Neurotox Res; 2007 Sep; 12(2):125-34. PubMed ID: 17967736
[TBL] [Abstract][Full Text] [Related]
9. Progressive nigrostriatal terminal dysfunction and degeneration in the engrailed1 heterozygous mouse model of Parkinson's disease.
Nordströma U; Beauvais G; Ghosh A; Pulikkaparambil Sasidharan BC; Lundblad M; Fuchs J; Joshi RL; Lipton JW; Roholt A; Medicetty S; Feinstein TN; Steiner JA; Escobar Galvis ML; Prochiantz A; Brundin P
Neurobiol Dis; 2015 Jan; 73():70-82. PubMed ID: 25281317
[TBL] [Abstract][Full Text] [Related]
10. Manganese exposure exacerbates progressive motor deficits and neurodegeneration in the MitoPark mouse model of Parkinson's disease: Relevance to gene and environment interactions in metal neurotoxicity.
Langley MR; Ghaisas S; Ay M; Luo J; Palanisamy BN; Jin H; Anantharam V; Kanthasamy A; Kanthasamy AG
Neurotoxicology; 2018 Jan; 64():240-255. PubMed ID: 28595911
[TBL] [Abstract][Full Text] [Related]
11. To what extent may aminochrome increase the vulnerability of dopaminergic neurons in the context of Parkinson's disease.
Chagraoui A; Anouar Y; De Deurwaerdere P; Arias HR
Int J Biochem Cell Biol; 2024 Mar; 168():106528. PubMed ID: 38246261
[TBL] [Abstract][Full Text] [Related]
12. Protective and toxic roles of dopamine in Parkinson's disease.
Segura-Aguilar J; Paris I; Muñoz P; Ferrari E; Zecca L; Zucca FA
J Neurochem; 2014 Jun; 129(6):898-915. PubMed ID: 24548101
[TBL] [Abstract][Full Text] [Related]
13. Adenosinergic protection of dopaminergic and GABAergic neurons against mitochondrial inhibition through receptors located in the substantia nigra and striatum, respectively.
Alfinito PD; Wang SP; Manzino L; Rijhsinghani S; Zeevalk GD; Sonsalla PK
J Neurosci; 2003 Nov; 23(34):10982-7. PubMed ID: 14645494
[TBL] [Abstract][Full Text] [Related]
14. Native DIGE proteomic analysis of mitochondria from substantia nigra and striatum during neuronal degeneration and its compensation in an animal model of early Parkinson's disease.
Kuter K; Kratochwil M; Marx SH; Hartwig S; Lehr S; Sugawa MD; Dencher NA
Arch Physiol Biochem; 2016 Dec; 122(5):238-256. PubMed ID: 27467289
[TBL] [Abstract][Full Text] [Related]
15. Conditional deletion of Ndufs4 in dopaminergic neurons promotes Parkinson's disease-like non-motor symptoms without loss of dopamine neurons.
Choi WS; Kim HW; Tronche F; Palmiter RD; Storm DR; Xia Z
Sci Rep; 2017 Mar; 7():44989. PubMed ID: 28327638
[TBL] [Abstract][Full Text] [Related]
16. LRRK2 BAC transgenic rats develop progressive, L-DOPA-responsive motor impairment, and deficits in dopamine circuit function.
Sloan M; Alegre-Abarrategui J; Potgieter D; Kaufmann AK; Exley R; Deltheil T; Threlfell S; Connor-Robson N; Brimblecombe K; Wallings R; Cioroch M; Bannerman DM; Bolam JP; Magill PJ; Cragg SJ; Dodson PD; Wade-Martins R
Hum Mol Genet; 2016 Mar; 25(5):951-63. PubMed ID: 26744332
[TBL] [Abstract][Full Text] [Related]
17. Auraptene Mitigates Parkinson's Disease-Like Behavior by Protecting Inhibition of Mitochondrial Respiration and Scavenging Reactive Oxygen Species.
Jang Y; Choo H; Lee MJ; Han J; Kim SJ; Ju X; Cui J; Lee YL; Ryu MJ; Oh ES; Choi SY; Chung W; Kweon GR; Heo JY
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31336718
[TBL] [Abstract][Full Text] [Related]
18. Cholesterol contributes to dopamine-neuronal loss in MPTP mouse model of Parkinson's disease: Involvement of mitochondrial dysfunctions and oxidative stress.
Paul R; Choudhury A; Kumar S; Giri A; Sandhir R; Borah A
PLoS One; 2017; 12(2):e0171285. PubMed ID: 28170429
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic activation of autophagy by combined treatment with rapamycin and trehalose in a mouse MPTP-induced model of Parkinson's disease.
Pupyshev AB; Tikhonova MA; Akopyan AA; Tenditnik MV; Dubrovina NI; Korolenko TA
Pharmacol Biochem Behav; 2019 Feb; 177():1-11. PubMed ID: 30582934
[TBL] [Abstract][Full Text] [Related]
20. Kir6.1/K-ATP channel on astrocytes protects against dopaminergic neurodegeneration in the MPTP mouse model of Parkinson's disease via promoting mitophagy.
Hu ZL; Sun T; Lu M; Ding JH; Du RH; Hu G
Brain Behav Immun; 2019 Oct; 81():509-522. PubMed ID: 31288070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
